JP2009521228A - 単球の樹状細胞への分化を促進する多孔質膜デバイス - Google Patents
単球の樹状細胞への分化を促進する多孔質膜デバイス Download PDFInfo
- Publication number
- JP2009521228A JP2009521228A JP2008547637A JP2008547637A JP2009521228A JP 2009521228 A JP2009521228 A JP 2009521228A JP 2008547637 A JP2008547637 A JP 2008547637A JP 2008547637 A JP2008547637 A JP 2008547637A JP 2009521228 A JP2009521228 A JP 2009521228A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- well
- porous membrane
- endothelial cells
- endothelial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 188
- 239000012528 membrane Substances 0.000 title claims description 155
- 210000001616 monocyte Anatomy 0.000 title abstract description 118
- 230000004069 differentiation Effects 0.000 title description 41
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 109
- 238000000034 method Methods 0.000 claims abstract description 86
- 102000036639 antigens Human genes 0.000 claims abstract description 63
- 108091007433 antigens Proteins 0.000 claims abstract description 63
- 239000000427 antigen Substances 0.000 claims abstract description 61
- 210000004027 cell Anatomy 0.000 claims description 143
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 53
- 239000000463 material Substances 0.000 claims description 47
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 45
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 45
- 210000002744 extracellular matrix Anatomy 0.000 claims description 45
- 102000008186 Collagen Human genes 0.000 claims description 44
- 108010035532 Collagen Proteins 0.000 claims description 44
- 229920001436 collagen Polymers 0.000 claims description 44
- 239000004417 polycarbonate Substances 0.000 claims description 34
- 229920000515 polycarbonate Polymers 0.000 claims description 33
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 19
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000002609 medium Substances 0.000 claims description 13
- 239000000758 substrate Substances 0.000 claims description 12
- 210000000265 leukocyte Anatomy 0.000 claims description 10
- 210000004698 lymphocyte Anatomy 0.000 claims description 9
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 9
- 239000011148 porous material Substances 0.000 claims description 9
- 239000006143 cell culture medium Substances 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- -1 protosan Substances 0.000 claims description 7
- 229920001661 Chitosan Polymers 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 210000002536 stromal cell Anatomy 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000770 proinflammatory effect Effects 0.000 claims description 4
- 210000003606 umbilical vein Anatomy 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 229960000074 biopharmaceutical Drugs 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract description 38
- 102000004127 Cytokines Human genes 0.000 abstract description 26
- 108090000695 Cytokines Proteins 0.000 abstract description 26
- 230000005012 migration Effects 0.000 abstract description 22
- 238000013508 migration Methods 0.000 abstract description 22
- 230000005867 T cell response Effects 0.000 abstract description 21
- 238000000338 in vitro Methods 0.000 abstract description 14
- 230000000139 costimulatory effect Effects 0.000 abstract description 12
- 230000001939 inductive effect Effects 0.000 abstract description 5
- 230000004962 physiological condition Effects 0.000 abstract description 5
- 230000036737 immune function Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 2
- 210000004379 membrane Anatomy 0.000 description 108
- 210000001744 T-lymphocyte Anatomy 0.000 description 36
- 239000010410 layer Substances 0.000 description 35
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 32
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 22
- 239000002356 single layer Substances 0.000 description 20
- 230000001464 adherent effect Effects 0.000 description 19
- 230000003511 endothelial effect Effects 0.000 description 17
- 239000003550 marker Substances 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 239000011324 bead Substances 0.000 description 14
- 230000001617 migratory effect Effects 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 230000012292 cell migration Effects 0.000 description 11
- 230000035800 maturation Effects 0.000 description 11
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 239000012911 assay medium Substances 0.000 description 9
- 238000009792 diffusion process Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 8
- 241000222122 Candida albicans Species 0.000 description 7
- 102000006354 HLA-DR Antigens Human genes 0.000 description 7
- 108010058597 HLA-DR Antigens Proteins 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 238000010899 nucleation Methods 0.000 description 7
- 101150013553 CD40 gene Proteins 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
- 229920000392 Zymosan Polymers 0.000 description 6
- 229940095731 candida albicans Drugs 0.000 description 6
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000013553 cell monolayer Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 3
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 108010073807 IgG Receptors Proteins 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001365 lymphatic vessel Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 210000004976 peripheral blood cell Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000013334 tissue model Methods 0.000 description 2
- BPVHBBXCESDRKW-UHFFFAOYSA-N 5(6)-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21.C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BPVHBBXCESDRKW-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000008212 P-Selectin Human genes 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 244000078885 bloodborne pathogen Species 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000046661 human PECAM1 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000006226 wash reagent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/44—Fungal antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/12—Well or multiwell plates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/20—Material Coatings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/02—Membranes; Filters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/28—Vascular endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Sustainable Development (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Clinical Laboratory Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75203305P | 2005-12-21 | 2005-12-21 | |
| PCT/US2006/049128 WO2007076061A1 (en) | 2005-12-21 | 2006-12-21 | A porous membrane device that promotes the differentiation of monocytes into dendritic cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009521228A true JP2009521228A (ja) | 2009-06-04 |
| JP2009521228A5 JP2009521228A5 (enExample) | 2012-04-12 |
Family
ID=37963795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008547637A Pending JP2009521228A (ja) | 2005-12-21 | 2006-12-21 | 単球の樹状細胞への分化を促進する多孔質膜デバイス |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20070178076A1 (enExample) |
| EP (2) | EP1963491B1 (enExample) |
| JP (1) | JP2009521228A (enExample) |
| AT (2) | ATE495238T1 (enExample) |
| AU (1) | AU2006330951B2 (enExample) |
| CA (2) | CA2634119C (enExample) |
| DE (1) | DE602006019638D1 (enExample) |
| IL (1) | IL192090A (enExample) |
| WO (1) | WO2007076061A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018537116A (ja) * | 2015-12-17 | 2018-12-20 | ロレアル | いくつかの直径の細孔を含む再構築された組織のための膜 |
| JP2019531717A (ja) * | 2016-09-08 | 2019-11-07 | サノフィ パスツール ヴァックスデザイン コーポレーション | インビトロの新生児バイオミメティック（ｎｍｉｍｉｃ）モデル及び方法、並びにその使用 |
| US12359153B2 (en) * | 2016-11-24 | 2025-07-15 | AlveoliX Technologies AG | Cell culturing system and method |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855074B2 (en) | 2004-04-28 | 2010-12-21 | Vaxdesign Corp. | Artificial immune system: methods for making and use |
| US7785806B2 (en) | 2004-04-28 | 2010-08-31 | Vaxdesign Corporation | Method for determining the immunogenicity of an antigen |
| US8298824B2 (en) | 2004-04-28 | 2012-10-30 | Sanofi Pasteur Vaxdesign Corporation | Methods of evaluating a test agent in a diseased cell model |
| US8030070B2 (en) * | 2004-04-28 | 2011-10-04 | Sanofi Pasteur Vaxdesign Corp. | Artificial lymphoid tissue equivalent |
| US7771999B2 (en) | 2004-04-28 | 2010-08-10 | Vaxdesign Corp. | Disease model incorporation into an artificial immune system (AIS) |
| US7709256B2 (en) * | 2004-04-28 | 2010-05-04 | Vaxdesign Corp. | Disease model incorporation into an artificial immune system (AIS) |
| US7785883B2 (en) | 2004-04-28 | 2010-08-31 | Vax Design Corp. | Automatable artificial immune system (AIS) |
| US8071373B2 (en) | 2004-04-28 | 2011-12-06 | Sanofi Pasteur Vaxdesign Corp. | Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS) |
| US8003387B2 (en) | 2005-12-21 | 2011-08-23 | Sanofi Pasteur Vaxdesign Corp. | In vitro germinal centers |
| JP2009521228A (ja) * | 2005-12-21 | 2009-06-04 | ヴァックスデザイン コーポレーション | 単球の樹状細胞への分化を促進する多孔質膜デバイス |
| ATE525093T1 (de) * | 2006-06-27 | 2011-10-15 | Sanofi Pasteur Vaxdesign Corp | Modelle für die bewertung von impfstoffen |
| US8647837B2 (en) * | 2007-07-16 | 2014-02-11 | Sanofi Pasteur Vaxdesign Corp. | Artificial tissue constructs comprising alveolar cells and methods for using the same |
| AU2010225438A1 (en) * | 2009-03-17 | 2011-10-13 | The Heart Research Institute Ltd | Method of cell differentiation and uses therefor in screening, diagnosis and therapy |
| US8802747B2 (en) * | 2009-08-26 | 2014-08-12 | Molecular Imprints, Inc. | Nanoimprint lithography processes for forming nanoparticles |
| US10731129B2 (en) | 2012-03-07 | 2020-08-04 | Children's Medical Center Corporation | Methods of evaluating immunogenicity of an agent using an artificial tissue construct |
| US9423234B2 (en) | 2012-11-05 | 2016-08-23 | The Regents Of The University Of California | Mechanical phenotyping of single cells: high throughput quantitative detection and sorting |
| KR101986092B1 (ko) * | 2016-09-13 | 2019-06-05 | 대한뉴팜(주) | 유두진피 섬유아세포의 고순도 분리 방법 |
| US11175282B2 (en) | 2017-06-26 | 2021-11-16 | Biohope Scientfic Solutions For Human Health S.L. | Method for predicting and monitoring clinical response to immunomodulatory therapy |
| CN112221543B (zh) * | 2019-07-15 | 2024-05-10 | 京东方科技集团股份有限公司 | 细胞片层转移器件、运输装置和转移细胞片层的方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10508522A (ja) * | 1994-11-08 | 1998-08-25 | オーガノジェネシス・インコーポレーテッド | イン・ビトロ組織および器官相当モデル |
| WO2005104755A2 (en) * | 2004-04-28 | 2005-11-10 | Vaxdesign Corporation | Artificial immune system: methods for making and use |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5160490A (en) * | 1986-04-18 | 1992-11-03 | Marrow-Tech Incorporated | Three-dimensional cell and tissue culture apparatus |
| US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| US5008116A (en) * | 1988-11-14 | 1991-04-16 | Frederick Cahn | Immunostimulatory microsphere |
| US5562910A (en) * | 1989-09-25 | 1996-10-08 | University Of Utah Research Foundation | Vaccine compositions and method for enhancing an immune response |
| US5188959A (en) * | 1989-09-28 | 1993-02-23 | Trustees Of Tufts College | Extracellular matrix protein adherent t cells |
| US5695996A (en) * | 1994-09-23 | 1997-12-09 | The United States Of America As Represented By The Department Of Health And Human Services | Artificial organ culture system |
| US6479258B1 (en) * | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US5739001A (en) * | 1996-10-29 | 1998-04-14 | E. I. Du Pont De Nemours And Company | Solid phase cell-based assay |
| US6177282B1 (en) * | 1997-08-12 | 2001-01-23 | Mcintyre John A. | Antigens embedded in thermoplastic |
| ATE428769T1 (de) * | 1997-10-27 | 2009-05-15 | Univ Rockefeller | Methode und zusammensetzung zur herstellung von reifen dendritischen zellen |
| US6835550B1 (en) * | 1998-04-15 | 2004-12-28 | Genencor International, Inc. | Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
| US20020155108A1 (en) * | 1998-05-04 | 2002-10-24 | Biocrystal, Ltd. | Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells |
| HK1046004B (en) * | 1999-11-12 | 2013-11-08 | Fibrogen, Inc. | Recombinant gelatins |
| EP1231836A4 (en) * | 1999-11-17 | 2004-06-02 | Univ Rochester | EX VIVO HUMAN IMMUNE SYSTEM |
| US6479064B1 (en) * | 1999-12-29 | 2002-11-12 | Children's Medical Center Corporation | Culturing different cell populations on a decellularized natural biostructure for organ reconstruction |
| US6541225B1 (en) * | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
| JP2004522446A (ja) * | 2001-02-07 | 2004-07-29 | コリア アトミック エネルギー リサーチ インスティテュート | 上皮細胞の分離方法、細胞を前条件付けする方法、およびバイオ人工皮膚もしくは真皮を上皮細胞または条件付けされた細胞を用いて調製する方法 |
| EP1437147B1 (en) * | 2001-09-25 | 2012-06-27 | National Institute for Environmental Studies | Method of preparing basement membrane |
| FR2833271B1 (fr) * | 2001-12-10 | 2004-09-17 | Coletica | Production de cellules dendritiques in vitro a partir de monocytes cd14+, pour notamment la realisation de modeles cellulaires et/ou tissulaires en suspension, en monocouches et tridimentionnels; utilisation de ces modeles |
| GB0130789D0 (en) * | 2001-12-21 | 2002-02-06 | King S College London | Application of spores |
| CA2480011A1 (en) * | 2002-03-18 | 2003-12-04 | Sciperio, Inc. | Dentritic cell nodes |
| EP2322928A1 (en) * | 2002-04-11 | 2011-05-18 | Cyclex, Inc. | Method for monitoring the immune response and predicting clinical outcomes in transplant recipients using ATP measurement in lymphocytes |
| US20040009943A1 (en) * | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Pathogen vaccines and methods for using the same |
| US20050191743A1 (en) * | 2002-10-03 | 2005-09-01 | Wu J.H. D. | Three-dimensional peripheral lymphoid organ cell cultures |
| US20040109876A1 (en) * | 2002-11-25 | 2004-06-10 | Kureha Chemical Industry Co., Ltd. | Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV |
| US7785806B2 (en) * | 2004-04-28 | 2010-08-31 | Vaxdesign Corporation | Method for determining the immunogenicity of an antigen |
| US8030070B2 (en) * | 2004-04-28 | 2011-10-04 | Sanofi Pasteur Vaxdesign Corp. | Artificial lymphoid tissue equivalent |
| US8071373B2 (en) * | 2004-04-28 | 2011-12-06 | Sanofi Pasteur Vaxdesign Corp. | Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS) |
| US7855074B2 (en) * | 2004-04-28 | 2010-12-21 | Vaxdesign Corp. | Artificial immune system: methods for making and use |
| US20070141552A1 (en) * | 2004-04-28 | 2007-06-21 | Warren William L | Automatable artificial immune system (AIS) |
| US20060275270A1 (en) * | 2004-04-28 | 2006-12-07 | Warren William L | In vitro mucosal tissue equivalent |
| US7771999B2 (en) * | 2004-04-28 | 2010-08-10 | Vaxdesign Corp. | Disease model incorporation into an artificial immune system (AIS) |
| US7785883B2 (en) * | 2004-04-28 | 2010-08-31 | Vax Design Corp. | Automatable artificial immune system (AIS) |
| JP2009521228A (ja) * | 2005-12-21 | 2009-06-04 | ヴァックスデザイン コーポレーション | 単球の樹状細胞への分化を促進する多孔質膜デバイス |
| US8003387B2 (en) * | 2005-12-21 | 2011-08-23 | Sanofi Pasteur Vaxdesign Corp. | In vitro germinal centers |
| ATE525093T1 (de) * | 2006-06-27 | 2011-10-15 | Sanofi Pasteur Vaxdesign Corp | Modelle für die bewertung von impfstoffen |
| CA2692689A1 (en) * | 2007-07-06 | 2009-01-15 | Vaxdesign Corporation | Rapid generation of t cell-independent antibody responses to t cell-dependent antigens |
-
2006
- 2006-12-21 JP JP2008547637A patent/JP2009521228A/ja active Pending
- 2006-12-21 DE DE602006019638T patent/DE602006019638D1/de active Active
- 2006-12-21 WO PCT/US2006/049128 patent/WO2007076061A1/en not_active Ceased
- 2006-12-21 US US11/642,926 patent/US20070178076A1/en not_active Abandoned
- 2006-12-21 EP EP06848082A patent/EP1963491B1/en active Active
- 2006-12-21 CA CA2634119A patent/CA2634119C/en active Active
- 2006-12-21 AT AT06848082T patent/ATE495238T1/de not_active IP Right Cessation
- 2006-12-21 CA CA2847310A patent/CA2847310A1/en not_active Abandoned
- 2006-12-21 EP EP10151003A patent/EP2199384B1/en active Active
- 2006-12-21 AU AU2006330951A patent/AU2006330951B2/en active Active
- 2006-12-21 AT AT10151003T patent/ATE531793T1/de active
-
2008
- 2008-06-12 IL IL192090A patent/IL192090A/en active IP Right Grant
-
2009
- 2009-10-30 US US12/609,060 patent/US20100105135A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10508522A (ja) * | 1994-11-08 | 1998-08-25 | オーガノジェネシス・インコーポレーテッド | イン・ビトロ組織および器官相当モデル |
| WO2005104755A2 (en) * | 2004-04-28 | 2005-11-10 | Vaxdesign Corporation | Artificial immune system: methods for making and use |
Non-Patent Citations (7)
| Title |
|---|
| JPN6012017130; 血液フロンティア Ｖｏｌ．１１， Ｎｏ．８, 2001, ｐ．４７-５２ * |
| JPN6012017132; Ｓｃｉｅｎｃｅ Ｖｏｌ．２８２, 1998, ｐ．４８０-４８３ * |
| JPN6012017134; Ｂｌｏｏｄ Ｖｏｌ．１０６, 20050719, ｐ．２８１８-２８２６ * |
| JPN6012017136; Ａｒｔｈｒｉｔｉｓ Ｒｈｅｕｍａｔｉｓｍ Ｖｏｌ．５２， Ｎｏ．１１, 200511, ｐ．３４６０-３４６９ * |
| JPN6013000799; Ｊ．Ｉｍｍｕｎｏｌ． Ｖｏｌ．１６０, 1998, ｐ．２６７５-２６８３ * |
| JPN6013000802; Ｉｍｍｕｎｉｔｙ Ｖｏｌ．１３, 2000, ｐ．３２３-３３２ * |
| JPN6013000805; Ｅｕｒ．Ｊ．Ｉｍｍｕｎｏｌ． Ｖｏｌ．２６, 1996, ｐ．７５９-７６７ * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018537116A (ja) * | 2015-12-17 | 2018-12-20 | ロレアル | いくつかの直径の細孔を含む再構築された組織のための膜 |
| JP2019531717A (ja) * | 2016-09-08 | 2019-11-07 | サノフィ パスツール ヴァックスデザイン コーポレーション | インビトロの新生児バイオミメティック（ｎｍｉｍｉｃ）モデル及び方法、並びにその使用 |
| JP2021180673A (ja) * | 2016-09-08 | 2021-11-25 | サノフィ パスツール ヴァックスデザイン コーポレーション | インビトロの新生児バイオミメティック（ｎｍｉｍｉｃ）モデル及び方法、並びにその使用 |
| JP7274540B2 (ja) | 2016-09-08 | 2023-05-16 | サノフィ パスツール ヴァックスデザイン コーポレーション | インビトロの新生児バイオミメティック（ｎｍｉｍｉｃ）モデル及び方法、並びにその使用 |
| US12359153B2 (en) * | 2016-11-24 | 2025-07-15 | AlveoliX Technologies AG | Cell culturing system and method |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006330951A1 (en) | 2007-07-05 |
| DE602006019638D1 (de) | 2011-02-24 |
| IL192090A (en) | 2012-01-31 |
| IL192090A0 (en) | 2008-12-29 |
| CA2634119A1 (en) | 2007-07-05 |
| ATE531793T1 (de) | 2011-11-15 |
| ATE495238T1 (de) | 2011-01-15 |
| EP2199384B1 (en) | 2011-11-02 |
| WO2007076061A1 (en) | 2007-07-05 |
| US20100105135A1 (en) | 2010-04-29 |
| AU2006330951B2 (en) | 2012-04-05 |
| CA2847310A1 (en) | 2007-07-05 |
| CA2634119C (en) | 2015-02-24 |
| EP1963491B1 (en) | 2011-01-12 |
| EP1963491A1 (en) | 2008-09-03 |
| EP2199384A1 (en) | 2010-06-23 |
| US20070178076A1 (en) | 2007-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100105135A1 (en) | Porous membrane device that promotes the differentiation of monocytes into dendritic cells | |
| JP5101559B2 (ja) | ｉｎｖｉｔｒｏにおけるＣＤ１４陽性単球からの樹状細胞の産出 | |
| JP5795699B2 (ja) | 人工免疫システム：作製および使用方法 | |
| US5766944A (en) | T cell differentiation of CD34+ stem cells in cultured thymic epithelial fragments | |
| US7855074B2 (en) | Artificial immune system: methods for making and use | |
| IL191930A (en) | Methods for producing activated dendritic cells | |
| US20060275270A1 (en) | In vitro mucosal tissue equivalent | |
| US12291702B2 (en) | System and methods for immune cells expansion and activation in large scale | |
| Schanen et al. | A novel approach for the generation of human dendritic cells from blood monocytes in the absence of exogenous factors | |
| Paulnock | Macrophages: Practical Approach Series | |
| KR20090049620A (ko) | Ｃｄ14＋ 단구로부터 랑게르한스 세포 및/또는 진피/간질성 수지상 세포를 생성시키는 방법 | |
| Koch et al. | Isolation, enrichment, and culture of murine epidermal langerhans cells | |
| EP3510143B1 (en) | In vitro neonatal biomimetic (nmimic) model and methods of using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091221 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091221 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20110726 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20111129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120403 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130415 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130422 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140627 |